Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value
Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value
复制标题
DOI：
10.1053/j.sult.2019.03.003
复制
发表时间：
2019-08-01
影响因子：
1.1
通讯作者：
Longatto-Filho, Adhemar
中科院分区：
文献类型：
--
作者：
Malhone, Carolina;Longatto-Filho, Adhemar
肿瘤标志物可被描述为由瘤形成组织表达的分子产物（免疫组织化学），或由肿瘤代谢和分泌的分子产物，并在体液（如血液和尿液）中进行生物化学表征。它们可以作为肿瘤分期和分级的指标，也可用于监测对治疗的反应和预测复发、进展、转移的发展或甚至患者存活。不幸的是，在某些情况下，它们可能没有确定的临床潜力。已经进行了一些调查，特别是在过去的十年中，使用生物技术的方法，以确定新的潜在的肿瘤标志物。通过将这些发现转化为临床应用，可以促进准确的诊断和预后预测，并有助于个性化treatment.The审查的目的是描述一些生物标志物与潜在的使用在宫颈癌，卵巢癌和子宫内膜癌的临床设置。(C)2019爱思唯尔公司All rights reserved.
Tumors markers can be described as molecular products expressed by neoplasia tissues (immunohistochemistry), or metabolized and secreted by tumor and characterized biochemically in body fluids such as blood and urine. They may have utility as indicators of tumor stage and grade as well useful for monitoring responses to treatment and predicting recurrence, progression, development of metastases, or even patient survival. Unfortunately, in some cases they may have no identified clinical potential.Several investigations have been carried out, especially in the last decade, using biotechnological methods, in order to identify new potential tumor markers. By translating these findings into clinical use one may facilitate accurate diagnosis and prognostic prediction, and contribute to individualized treatment.The objective of this review is to describe some biomarkers with potential use in clinical settings of uterine cervix, ovary, and endometrium carcinomas. (C) 2019 Elsevier Inc. All rights reserved.